San Diego-based Anadys Pharmaceuticals (NASDAQ: [[ticker:ANDS]]) said today it has started a mid-stage clinical trial of its lead drug candidate, ANA598, for patients with hepatitis C. The study will enroll 90 patients on the drug or a placebo, in combination with the standard treatments—pegylated interferon alpha and ribavirin. Initial results on the anti-viral activity of the Anadys drug should be available by year-end, with more follow-up data to come in 2010, the company said. This ambitious trial design is part of what has brought Anadys back from some dark days earlier this year.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
